The combination of reported missed doses and pill counts was a significant predictor of compliance as measured by electronic monitoring. Electronic monitoring caps provided useful information only when they were used appropriately. Asking clients about missed doses and performing pill counts are the most practical assessments of compliance in practice.
The pharmacokinetics of ciprofloxacin was investigated in healthy, mature ponies. Ciprofloxacin was administered intravenously to six ponies at a dose of 5 mg per kg body weight. Seven days later, ciprofloxacin was administered orally to each pony at the same dose. Intravenous ciprofloxacin concentration vs. time data best fit a two-compartment open model with first-order elimination from the central compartment. Mean plasma half-life, based on the terminal phase, was 157.89 min (harmonic mean). Total body clearance of ciprofloxacin was 18.12 +/- 3.99 mL/min/kg. Volume of distribution at steady-state was 3.45 +/- 0.72 L/kg. From the pharmacokinetic data and reported minimum inhibitory concentrations for equine gram-negative pathogens, the appropriate dosage of ciprofloxacin was determined to be 5.32 mg per kg body weight at 12 h intervals. Bioavailability of oral ciprofloxacin in ponies was 6.8 +/- 5.33%. Owing to the poor bioavailability, a dosage regimen could not be proposed for oral ciprofloxacin administration in horses. Ciprofloxacin concentrations were determined in tissues and body fluids at 1, 2 and 4 h after intravenous administration. At all times, tissue concentrations exceeded plasma concentrations of ciprofloxacin. Highest concentrations were achieved in kidneys and urine. Potentially therapeutic concentrations were obtained in cerebrospinal and joint fluid, but low concentrations were achieved in aqueous humour.
Escherichia coli (n = 1439), isolated from the feces of apparently healthy grow-finish pigs in 20 herds, were tested for susceptibility to 16 antimicrobials. Logistic regression models were developed for each resistance that was observed in more than 5% of the isolates. Each production phase's (suckling, nursery, grow-finish pigs or sows) antimicrobial exposure rate, through feed or water, was considered as a risk factor. Management variables were evaluated as potential confounders. Six resistance outcomes were associated with an antimicrobial use risk factor and four included exposures of pigs outside the grow-finish phase. In the case of sulfamethoxazole, the odds of resistance increased 2.3 times for every 100,000 pig-days of nursery pig exposure to sulfonamides. Thus, swine producers and veterinarians must be aware that antimicrobial use in pigs distant from market could have food safety repercussions. Five resistance outcomes were associated with exposure to an unrelated antimicrobial class. Most notably, the odds of sulfamethoxazole and chloramphenicol resistance were each six times higher in herds reporting high (more than 500/1,000 pig-days) grow-finish pig, macrolide exposure compared to herds with no macrolide use in grow-finish pigs. Therefore, the potential for co-selection should be considered in antimicrobial use decisions. This study emphasizes the importance of judicious antimicrobial use in pork production.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.